► Aicardi-Goutières syndrome ► bilateral striatal necrosis ► spastic paraparesis ► dystonia ► idiopathic basal ganglia calcification
Introduction
Adenosine deaminases acting on RNA (ADARs) catalyze the hydrolytic deamination of adenosine to inosine in doublestranded RNA, and thereby potentially alter the information content and structure of cellular RNAs.
1 ADAR1 is encoded by a single-copy gene that maps to human chromosome 1q21 and is present in two main isoforms in mammalian cells. In mice, a loss of ADAR1 activity leads to a dramatic upregulation of interferon-stimulated gene (ISG) expression, which is dependent on the editing activity of ADAR1 and specific to the interferon-inducible full-length p150 isoform of the protein.
2-4
In 2012, we reported mutations in ADAR1 to cause a phenotype consistent with the infantile encephalopathy Aicardi-Goutières syndrome (AGS), and demonstrated that, similar to the ADAR1 null mouse, the mutant genotype was associated with an upregulation of type I interferon signaling.
5
Further to this, in 2014, we described both bilateral striatal necrosis (BSN), sometimes occurring after a trivial childhood infection, and otherwise nonsyndromic, slowly progressive spastic paraparesis associated with normal intellect occur due to ADAR1 dysfunction, again in association with the enhanced expression of type I interferon-induced gene transcripts. [6] [7] [8] These data indicate that neurological disease can occur through inappropriate induction of the innate immune system by self-derived nucleic acids.
Here, we present an update of our experience of screening for ADAR1 mutations, describing the clinical, radiological, molecular, and interferon biomarker characteristics of a cohort of 46 patients from 37 families with neurological dysfunction due to mutations in ADAR1.
Materials and Methods

Patients and Methods
We ascertained clinical and molecular data through direct contact and/or via collaborating physicians. The study was approved by the Leeds (East) Research Ethics Committee (reference number 10/H1307/132), and the Comité de Protection des Personnes (ID-RCB/EUDRACT: 2014-A01017-40).
A diagnosis of AGS was suggested by characteristic clinical and neuroimaging features including cerebral atrophy, white matter disease, and intracranial calcification.
9 BSN was diagnosed in the context of an acute or subacute onset of a dystonic/rigid motor disorder associated with magnetic resonance imaging features of bilateral striatal signal change with or without swelling. Spastic paraparesis/tetraparesis and spastic dystonia were diagnosed according to clinical signs, in the presence of either normal neuroimaging or mild nonspecific changes sometimes including calcification of the basal ganglia. Assessment of the motor and communication status of patients over the age of 1 year was made using the Gross Motor Function Classification System (GMFCS), 10 the Manual Ability Classification System (MACS), 11 and the Communication Function Classification System (CFCS).
12
Mutational Analysis
Primers were designed to amplify the coding exons of ADAR1 (►Supplementary Table S1 , online-only). Purified polymerase chain reaction (PCR) amplification products were sequenced using BigDye terminator chemistry and an ABI 3130 DNA sequencer. Mutation description is based on the reference cDNA sequence NM_001111.4, with nucleotide numbering beginning from the first A in the initiating ATG codon. Variants were assessed using the in silico programs SIFT (http://sift.jcvi.org) and Polyphen2 (http://genetics. bwh.harvard.edu/pph2/), and population allele frequencies obtained from the ExAC (http://exac.broadinstitute.org) and gnomAD (http://gnomad.broadinstitute.org) databases.
Interferon Score
Whole blood was collected into PAXgene tubes, total RNA extracted using a PreAnalytix RNA isolation kit and RNA concentration assessed using a spectrophotometer (FLUOstar Omega, Labtech). Quantitative reverse transcription PCR (qPCR) analysis was performed using the TaqMan Universal PCR Master Mix (Applied Biosystems), and cDNA derived from 40 ng total RNA. Using TaqMan probes for IFI27 (Hs01086370_m1),
, RSAD2 (Hs01057264_m1), and SIGLEC1 (Hs00988063_m1), the relative abundance of each target transcript was normalized to the expression level of HPRT1 (Hs03929096_g1) and 18S (Hs999999001_s1), and assessed with the Applied Biosystems StepOne Software v2.1 and DataAssist Software v.3.01. For each of the six probes, individual data were expressed relative to a single calibrator. Relative quantification is equal to 2
ÀΔΔCt that is, the normalized fold change relative to the control data. The median fold change of the 6 genes compared with the median of 29 previously collected healthy controls is used to create an interferon score for each individual, with an abnormal interferon score being defined as greater than þ2 standard deviations above the mean of the control group, that is, 2.466.
Results
Molecular Data
We collected data on 46 patients from 37 families of panethnic origin with either biallelic mutations in ADAR1 (28 families) or the single known dominant-negative mutation p. Gly1007Arg (nine families) (►Table 1; ►Fig. 1). In four families, the p.Gly1007A mutation was considered to have occurred de novo, while in three families, inheritance was confirmed or inferred (two paternal half-siblings born to an unaffected father unavailable for testing), with somatic mosaicism recorded in one case. In two families, inheritance could not be determined because DNA from both parents was not available. We observed three distinct homozygous mutations in five families (two families each sharing the same mutation), in four of which the parents were knowingly related. All of these mutations were missense. Of 23 families with compound heterozygous mutations, 22 carried the p. Pro193Ala mutation on one allele. In 13 of 22 families segregating this p.Pro193Ala substitution, the second molecular lesion was a null or splicing variant.
Clinical Radiological Phenotype
Clinical radiological characteristics of all patients are summarized in ►Table 2, and characteristic radiological appearances are summarized in ►Fig. 2. Median age of disease onset was 14 months (range: birth-30 years). We observed 21 and 25 affected females and males, respectively. Although spasticity and dystonia were common features present in the majority of patients, clinically and radiologically distinct phenotypes could be defined, including classical AGS (15 patients), BSN (16 patients), apparently isolated spastic paraparesis (1 patient)/tetraparesis (2 patients), and a progressive spastic dystonic motor disorder (7 patients). In two of these latter cases, the initial presentation was of isolated lower limb spasticity, with a dystonic component and involvement of the upper limbs only becoming evident several years later. Four patients demonstrated radiological features of both AGS and BSN. The mother of a child with an AGS presentation was diagnosed at the age of 30 years with subtle psychological features and marked intracranial calcification. We identified three patients with significant neurological disease (a spastic/dystonic phenotype) in the absence of changes on brain imaging at presentation. A total of 25 patients were considered to have demonstrated normal development prior to disease onset, in 18 of whom there was a history of either vaccination (4 patients) or a notable infectious episode (14 patients) in the period shortly preceding the development of clinical signs (►Fig. 3A). Several patients experienced a rapid onset of dystonia/spasticity and loss of skills, with two patients being admitted to intensive care due to severe dystonic crisis. Others exhibited a more slowly progressive onset over weeks Neurological Disease due to ADAR1 Dysfunction Rice et al. 16
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or months. Definite clinical progression beyond the initial presentation was recorded in 16 cases. Nine patients are deceased, between the ages of 10 months and 19 years, six of whom had early-onset disease consistent with AGS. An assessment of gross motor function, manual ability, and communication status at last contact was made in 45 patients, of whom 27 were recorded to have none of any purposeful gross motor, hand and communication function (score of 5 on all three scales) (►Fig. 3B). Five patients were able to walk with no or some support (GMFCS I-III). Eleven patients were capable of effective sender and receiver communication (CFCS I-III). Although formal testing was not undertaken, seven patients were considered to have normal intellectual function.
Five patients were reported to demonstrate hypo/hyperpigmentation consistent with dyschromatosis symmetrica hereditaria (DSH) 1, and two patients were described with chilblain-like vasculitic lesions. Four patients were documented with autoimmune hemolytic anemia. Glaucoma was not recorded in any patient.
Interferon Status
We derived 52 interferon scores from 34 patients, 50 of which were abnormal, with a median interferon score across the group of 16.99 (interquartile range [IQR]: 10.64-25.71) compared with controls (median: 0.93, IQR: 0.57-1.30) (►Fig. 4). Positive scores were observed up to 25 years after disease onset. We also tested 20 interferon scores from 16 parental carriers of a recessive mutation in ADAR1. Two samples from seven parents heterozygous for the recurrent p.Pro193Ala mutation demonstrated a positive interferon score, versus six samples from nine parents carrying a different mutation (►Supplementary Fig. S1 , online-only).
Discussion
In 2012, ADAR1 mutations were described in the context of the early-onset encephalopathy AGS, associated with the presence of intracranial calcification, white matter disease, and severe developmental delay. 5 Subsequently, in 2014, mutations in ADAR1 were also shown to underlie cases of apparently nonsyndromic BSN, and of isolated spastic paraparesis with normal neuroimaging. 6,7 Here, we confirm these associations, thus emphasizing the need to consider ADAR1-related disease in several distinct clinical scenarios triggering different investigative algorithms. Furthermore, we now describe a patient with a dominant-negative mutation in ADAR1 demonstrating an adult-onset phenotype evocative of "idiopathic" basal ganglia calcification characterized by intracranial calcification and subtle psychological disturbance. Our clinical and radiological findings highlight the propensity of ADAR1-related disease to incur basal ganglia dysfunction, and the value of basal ganglia calcification, frequently only appreciated on computed tomography, as a diagnostic indicator. In general, mutations in ADAR1 should be considered in the context of a motor disorder characterized by spasticity and dystonia. The onset of disease can occur after a period of normal development, sometimes associated with a rapid loss of skills, or a much slower progression over many years. Assessments using the GMFCS, MACS, and CFCS rating scales indicate that disease outcome in the cases that we have ascertained is frequently severe. It is of note that we observed cases with completely preserved intellect þ/À normal neuroimaging in the face of significant motor disability. Our own research focus is biased toward the ascertainment of pediatric disease. However, Tojo et al described a female patient with the dominant-negative p.Gly1007Arg mutation, presenting at the age of 17 years with gait disturbance and dystonic posturing of the legs, who experienced intellectual deterioration from 21 years of age, and became wheelchair bound a year later.
13 Together with our observation of an adult female whose clinical phenotype only became evident at the age of 30 years, it is clear that later onset disease can occur due to ADAR1 deficiency. This latter case also illustrates the significant intrafamilial variability which can be seen in association with ADAR1 dysfunction, the mother presenting in adulthood with subtle psychological disturbance, while her son experienced a devastating early-onset encephalopathy. ADAR1-related neurological disease can be inherited as either an autosomal recessive or autosomal dominant trait. We observed homozygosity for a missense mutation in five of 28 families segregating recessive disease. As previously suggested, the absence of patients with homozygous null mutations indicates that, as for the ADAR1 null mouse, complete loss of ADAR1 protein activity is likely embryonic lethal.
5 Our molecular data reveal a remarkably high frequency of the p.Pro193Ala substitution, seen in 22 of 23 families with compound heterozygous molecular lesions in ADAR1. This mutation, which is recorded on 602 of 282,636 alleles in the gnomAD database, was not observed in the homozygous state in our cohort. That this variant was seen in combination with a null mutation in 13 families suggests that homozygosity for the p.Pro193Ala allele leads to a milder, later onset, or distinct phenotype not ascertained here, or may not be associated with disease. Perhaps of note, the gnomAD database includes one individual homozygous for this mutation. Finally, our molecular data highlight the dominant-negative p.Gly1007Arg mutation, which can occur de novo, or be inherited with variable expression and/or nonpenetrance at least into mid-adult life. The proximity of Gly1007 to the backbone of its RNA ligand, and the possibility for an arginine residue to make polyvalent interactions there suggests a mechanism whereby Arg1007 might bind more tightly to RNA and thus act as a competitive inhibitor of wild-type protein, while being itself catalytically inactive.
14
In keeping with this model, we previously demonstrated that a plasmid expressing Gly1007Arg showed stronger inhibition of wild-type ADAR1 than equivalent amounts of a plasmid expressing catalytic inactive ADAR1.
5
More than 130 different ADAR1 mutations have been documented in patients with DSH, an autosomal-dominant disorder characterized by the childhood onset of hypopigmented and hyperpigmented macules on the face and dorsal aspects of the extremities.
15 DSH has only very rarely been reported outside of Japan and China, and even within identified families, a marked variability in expression is well recognized. In our series, five patients were noted to demonstrate pigmentary lesions consistent with DSH. The frequent observation of stop and frameshift variants in DSH indicates haploinsufficiency as the likely molecular pathology, consistent with the recent confirmation of our previous suggestion that two individuals with DSH would be at one in four risk of a pregnancy with ADAR1-related neurological disease.
16
Loss-of-function mutations in ADAR1 have been classified within the so-called type I interferonopathy grouping, a novel set of inborn errors of immunity where it is proposed that an upregulation of type I interferon signaling is central to disease pathogenesis. 17, 18 The AGS phenotype can arise due to mutations in any one of seven genotypes within this Neurological Disease due to ADAR1 Dysfunction Rice et al. 175
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Neurological Disease due to ADAR1 Dysfunction Rice et al. 177
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Neurological Disease due to ADAR1 Dysfunction Rice et al. 17
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. grouping (AGS1-7: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1), and apparently isolated spastic paraparesis has been reported in patients mutated in three of these genes (RNASEH2B, ADAR1, and IFIH1). In contrast, in an overview of 374 patients from 299 families with mutations in AGS1-7, BSN, the most frequently ascertained phenotype in the current series, was only recorded in the context of ADAR1-related disease, suggesting discrete factors relevant to gene/protein expression and disease mechanism consequent upon ADAR1 dysfunction. 19 Also possibly reflective of this apparent specificity, in comparison to other genotypes, is the frequency of clinical progression, and the low risk of developing glaucoma and chilblain-like lesions (since we recorded no examples of the former and only two cases of the latter in our cohort).
The consistent finding of a positive interferon signature in peripheral blood in the series of patients reported here indicates the potential utility of this biomarker as a screening test for ADAR1-related disease, for the interpretation of ADAR1 genetic sequence variants of uncertain significance, and in the possible monitoring of treatment efficacy as antiinterferon therapies is developed. 20, 21 We emphasize that the interferon signature remains elevated many years after disease onset, providing evidence of ongoing pathology. ADAR1 is expressed throughout the brain including the basal ganglia (http://www.brain-map.org), and it has been shown that a loss of ADAR1 renders cells more susceptible to apoptosis following stress, including infection. 22 We cannot rule out the possibility that the occurrence of fevers prior to frank neurological regression represents a prodrome in some cases. However, a history of vaccination or an apparently discrete infectious episode in several patients considered to be completely developmentally normal prior to disease onset, of whom 12 demonstrated BSN on neuroimaging, raises the possibility that the acute degeneration of striatal tissue seen in many patients with ADAR1 mutations might relate to a rapid induction of apoptosis triggered by viral infection/metabolic stress. Beyond this possibility, there is strong evidence that interferon is a neurotoxin, 23-27 and we consider it likely that inappropriate and chronic exposure to type I interferons may be directly relevant to the ADAR1-related neurological phenotypes described here, perhaps induced by dsRNA species which are normally edited by ADAR1, thereby rendering them as immunology inert/ marking them as self. 1, 3, 4, 28 These observations highlight the potential utility of treatments for ADAR1-related disease, which recent data suggest might be usefully targeted at antagonism of type I interferon signaling. 
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